Accessibility Menu
 
Cytek Biosciences logo

Cytek Biosciences

(NASDAQ) CTKB

Current Price$3.83
Market Cap$486.87M
Since IPO (2021)-80%
5 YearN/A
1 Year+42%
1 Month-18%

Cytek Biosciences Financials at a Glance

Market Cap

$486.87M

Revenue (TTM)

$204.17M

Net Income (TTM)

$74.00M

EPS (TTM)

$-0.58

P/E Ratio

-6.53

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$3.83

Volume

165,010.281

Open

$3.69

Previous Close

$3.77

Daily Range

$3.67 - $3.83

52-Week Range

$2.37 - $6.18

CTKB News

CTKB: Motley Fool Moneyball Superscore

52

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cytek Biosciences

Industry

Life Sciences Tools and Services

Employees

700

CEO

Wen Bin Jiang, PhD

Headquarters

Fremont, CA 94538, US

CTKB Financials

Key Financial Metrics (TTM)

Gross Margin

52%

Operating Margin

-21%

Net Income Margin

-36%

Return on Equity

-21%

Return on Capital

-12%

Return on Assets

-16%

Earnings Yield

-15.31%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$486.87M

Shares Outstanding

129.14M

Volume

165.01K

Avg. Volume

793.42K

Financials (TTM)

Gross Profit

$104.46M

Operating Income

$40.38M

EBITDA

$17.39M

Operating Cash Flow

$4.69M

Capital Expenditure

$4.08M

Free Cash Flow

$8.77M

Cash & ST Invst.

$261.53M

Total Debt

$23.74M

Cytek Biosciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$44.13M

+6.5%

Gross Profit

$21.25M

+5.4%

Gross Margin

48.16%

N/A

Market Cap

$486.87M

N/A

Market Cap/Employee

$734.34K

N/A

Employees

663

N/A

Net Income

$18.87M

-65.5%

EBITDA

$15.65M

-93.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$225.90M

-9.5%

Accounts Receivable

$56.48M

+2.3%

Inventory

$49.79M

+9.8%

Long Term Debt

$20.46M

+144.6%

Short Term Debt

$15.86M

+110.6%

Return on Assets

-16.48%

N/A

Return on Invested Capital

-11.92%

N/A

Free Cash Flow

$4.90M

-402.5%

Operating Cash Flow

$2.74M

-2088.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ANGOAngioDynamics, Inc.
$11.67-1.19%
KIDSOrthoPediatrics Corp.
$18.28-1.19%
VREXVarex Imaging Corporation
$10.04-0.87%
LABStandard BioTools Inc.
$1.04-1.42%

Trending Stocks

Symbol / CompanyPricePrice Chg
RGTIRigetti Computing
$21.18+0.26%
INFQInfleqtion
$14.50+0.30%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$14.77+0.01%
TET1 Energy Inc.
$9.27+0.07%

Questions About CTKB

What is the current price of Cytek Biosciences?

Cytek Biosciences is trading at $3.82 per share.

What is the 52-week range for Cytek Biosciences?

Over the past 52 weeks, Cytek Biosciences has traded between $2.37 and $6.18.

How much debt does Cytek Biosciences have?

As of the most recent reporting period, Cytek Biosciences reported total debt of $36.33M.

How much cash does Cytek Biosciences have on hand?

Cytek Biosciences reported $65.67M in cash and cash equivalents in its most recent financial results.

What is Cytek Biosciences’s dividend yield?

Cytek Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.